Saphnelo (anifrolumab-fnia) for systemic lupus erythematosus
Customize your policy alerts
Sign up for Empire Bluecross Policy CC-0202 alerts
Get alerted when Policy CC-0202 changes without checking for updates manually.
Monitor payer policy activity
This policy governs medical-necessity and prior-authorization review for Saphnelo (anifrolumab-fnia) used to treat adults with moderate to severe systemic lupus erythematosus as add-on therapy, including applicable coding and quantity limits.
A Saphnelo 120 mg/0.8 mL syringe or autoinjector quantity limit was added.
HCPCS C9399 and J3590 were added for Saphnelo supplied as a subcutaneous product.
The restriction against using Saphnelo with cyclophosphamide was removed.
The diagnosis requirement for systemic lupus erythematosus was clarified to require American College of Rheumatology criteria and supporting antibody documentation.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.